BIIB112 for choroideremia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Jun 2018: Trial started, NCT03584165
  2. 12 Jul 2018: Trial registered, NCT03584165

The trials

NCT03584165: Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

State
Completed
Phase
Phase 3
People
277 taking part
Started
4 Jun 2018
Primary completion
22 Jun 2026
Arms
BIIB112
Results
None posted
  1. 4 Jun 2018: Trial started
  2. 12 Jul 2018: Trial registered
  3. 22 Jun 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.